Terran Biosciences

As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph, reported Noah Smith. 4-HO-DiPT is a...

New York-based biotech Terran Biosciences has signed an agreement with French pharmaceutical company Pierre Fabre Médicament for worldwide exclusive rights to develop and commercialize a list of the latter's assets targeting neuropsychiatric conditions. The licensing deal includes...

NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application covering what may be the first new salts, co-crystals and polymorphs of psilocybin in history. CEO Dr. Sam Clark stated the company believes the new forms of psilocybin “will...

Terran Biosciences, the NY-based biotech platform that develops transformational therapeutics announced the publication of four international PCT patent applications covering novel compounds and potentially improved versions of the empathogens methylone (also called bk-MDMA or MDMC...

New York-based therapeutics biotech platform Terran Biosciences published a new World International Patent Organization (WIPO) application under the Patent Cooperation Treaty (PCT) to protect its novel, non-hallucinogenic psychoplastogens inspired in DMT and ibogaine with improved drug...

Terran Biosciences Inc. is suing COMPASS Pathways (NASDAQ: CMPS) for the appropriation of trade secrets.    Terran, a private biotech platform company filed a complaint against COMPASS last Friday. On Monday, August 8, the case was assigned to District Judge Ellen Lipton...

Terran Biosciences is slowly but surely finding its place in the psychedelics industry. Last week, the company announced a licensing agreement with Big Pharma’s heavy-weight Sanofi (NASDAQ: SNY). Founded in 2017, Terran has maintained a low profile until recently. In early...